Cargando…

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease

Intestinal Behçet’s disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet’s disease is difficult to treat and often requires surgery because of the failure of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jihye, Cheon, Jae Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254627/ https://www.ncbi.nlm.nih.gov/pubmed/29788675 http://dx.doi.org/10.5009/gnl17462

Ejemplares similares

Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
por: Han, So Jung, et al.
Publicado: (2023)

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
por: Park, Jihye, et al.
Publicado: (2017)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Updated treatment strategies for intestinal Behçet’s disease
por: Park, Yong Eun, et al.
Publicado: (2018)

Outcome Predictors for Intestinal Behçet's Disease
por: Park, Jae Jun, et al.
Publicado: (2013)

Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience
por: Park, Jihye, et al.
Publicado: (2018)

Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
por: Cheon, Jae Hee
Publicado: (2021)

Efficacy of Anti-Tumor Necrosis Factor-α Therapy Against Intestinal Behçet’s Disease Complicated by Recurrent Enterocutaneous Fistulae
por: Kashima, Hitomi, et al.
Publicado: (2022)

Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease
por: Lee, Hyun Jung, et al.
Publicado: (2017)

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
por: Lee, Jung Hoon, et al.
Publicado: (2007)

Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?
por: Kim, Duk Hwan, et al.
Publicado: (2016)

Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report
por: Gulli, Salvatore, et al.
Publicado: (2003)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
por: Park, Jihye, et al.
Publicado: (2021)

Overlooked Management and Risk Factors for Anemia in Patients with Intestinal Behçet’s Disease in Actual Clinical Practice
por: Kim, Bun, et al.
Publicado: (2015)

Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis
por: Zhang, Qingfeng, et al.
Publicado: (2022)

The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet’s disease: a systematic review and meta-analysis
por: Mohammed, Reem Hamdy A, et al.
Publicado: (2023)

Cancer Risk in Patients with Intestinal Behçet’s Disease: A Nationwide Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2018)

Identification of genetic susceptibility loci for intestinal Behçet’s disease
por: Kim, Seung Won, et al.
Publicado: (2017)

C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet’s disease
por: Kang, Eun Ae, et al.
Publicado: (2021)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Radiation Exposure from Abdominal Imaging Studies in Patients with Intestinal Behçet Disease
por: Jung, Yoon Suk, et al.
Publicado: (2014)

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
por: Hyun, Hye Kyung, et al.
Publicado: (2022)

Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet’s Disease
por: Park, Jung Won, et al.
Publicado: (2018)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin
por: Park, Yong Eun, et al.
Publicado: (2021)

Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet’s disease: An updated meta-analysis
por: Zhang, Min, et al.
Publicado: (2013)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Diagnosis and management of intestinal Behçet’s disease
por: Hisamatsu, Tadakazu, et al.
Publicado: (2014)

The treatment principles and targets for intestinal Behcet’s disease
por: He, Kun, et al.
Publicado: (2023)

Interplay between chronic inflammation and clonal haematopoiesis of indeterminate potential in Behçet’s disease
por: Park, Jihye, et al.
Publicado: (2023)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy
por: Caso, Francesco, et al.
Publicado: (2014)

Intestinal Perforations in Behçet’s Disease
por: Chou, Shao-Jiun, et al.
Publicado: (2007)

Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis
por: Hu, Yunwei, et al.
Publicado: (2020)

Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
por: Cheon, Jae Hee, et al.
Publicado: (2023)

Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet’s disease
por: Lee, Hyun Jung, et al.
Publicado: (2019)

Correlation between Soluble Triggering Receptor Expressed on Myeloid Cells-1 and Endoscopic Activity in Intestinal Behçet's Disease
por: Lee, Hyun Jung, et al.
Publicado: (2014)

Incidence and Prevalence of Inflammatory Bowel Disease across Asia
por: Park, Jihye, et al.
Publicado: (2021)

Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
por: Pascual-Camps, Isabel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n6tmobisjcd8d8q7raird8ued3